Eurofins CDMO Alphora Inc., a contract drug and manufacturing organization based in Mississauga, recently announced the successful completion of its state-of-the-art 3,300 square feet pilot-scale Biologics development facility in Mississauga. Specializing in monoclonal antibodies (mAbs) and mammalian-based therapeutic proteins, the facility offers comprehensive services in upstream processing, downstream development, process design, GMP QC testing, with up to 200 L scale for Pre-Clinical and Phase I Supply. Additionally, the facility supports fully integrated conjugation services for antibody drug conjugate (ADC) candidate development, leveraging its extensive experience in active pharmaceutical ingredients (API) and highly potent active pharmaceutical ingredients (HPAPI).
We are pleased to count Eurofins CDMO Alphora as an OBIO® member, and also as a sponsor of the 2024 OBIO® Investment Summit.